Skip to main content
SpringerLink
Log in
Book cover

Hepatitis C Virus I pp 3–14Cite as

Towards the Control of Hepatitis C

  • Chapter
  • First Online:

Abstract

The discovery and characterisation of the hepatitis C virus (HCV) genome using a bacteriophage expression screening approach in 1989, quickly led to the development of blood tests to protect the blood supply and to diagnose and facilitate management of HCV patients. The viral-encoded serine protease and replicase then became major drug targets that in combination with viral NS5a-targeting drugs, that were facilitated by the use of in vitro genome replicon systems, has now led to most HCV patients being curable after just short treatment regimens. Natural immunity has been demonstrated in multiply-exposed individuals along with the identification of cellular immune correlates of protection. A growing role for neutralising antibodies in protection has also been indicated following the ability to grow HCV and viral pseudoparticles in cell culture. This knowledge has led to the pre-clinical and clinical testing of various promising vaccine candidates. Approval of HCV vaccines along with the development of much cheaper antiviral drugs will eventually lead to the effective global control of this virus which currently infects an estimated 150 million carriers around the world.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M (2015) Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 62(1):25–30. doi:10.1002/hep.27890. Epub 2015 Jun 1

    Article  CAS  PubMed  Google Scholar 

  • Alter HJ (1980) The dominant role of non-A, non-B in the pathogenesis of post-transfusion hepatitis: a clinical assessment. Clin Gastroenterol 9:155–170

    CAS  PubMed  Google Scholar 

  • Barakat KH, Anwar-Mohamed A, Tuszynski JA, Robins MJ, Tyrrell DL, Houghton M (2015) A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J Chem Inf Model 55(2):362–373. doi:10.1021/ci400631n. Epub 2014 Apr 14

    Article  CAS  PubMed  Google Scholar 

  • Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchot C (1997) Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. PNAS USA 94(4):1200–1205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bayer ME, Blumberg BS, Werner B (1968) Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s syndrome and hepatitis. Nature 218:1057–1059

    Article  CAS  PubMed  Google Scholar 

  • Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O’Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG (2014) Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem 57(5):2013–2032. doi:10.1021/jm401836p. Epub 2014 Feb 12

    Article  CAS  PubMed  Google Scholar 

  • Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290(5498):1972–1974

    Article  CAS  PubMed  Google Scholar 

  • Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood–borne non-A, non-B viral hepatitis genome. Science 244:359–362

    Article  CAS  PubMed  Google Scholar 

  • Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ et al (1991) Genetic organization and diversity of the hepatitis C virus. PNAS USA 88(6):2451–2455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G et al (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. PNAS USA 91:1294–1298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cox AL, Thomas DL (2013) Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 57(Suppl 2):S46–S50. doi:10.1093/cid/cit329

    Article  PubMed  PubMed Central  Google Scholar 

  • de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, Winer BY, Gerges S, Vega K, Labitt RN, Donovan BM, Giang E, Krishnan A, Chiriboga L, Charlton MR, Burton DR, Baltimore D, Law M, Rice CM, Ploss A (2014) Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med 6(254):254ra129. doi:10.1126/scitranslmed.3009512

    Article  PubMed  PubMed Central  Google Scholar 

  • Dienstag JL, Alter HJ (1986) Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective. Semin Liver Dis 6:67–68

    Article  CAS  PubMed  Google Scholar 

  • Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501(7466):237–241. doi:10.1038/nature12427. Epub 2013 Jul 31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Drummer HE (2014) Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol 5:329. doi:10.3389/fmicb.2014.00329. eCollection 2014

    Article  PubMed  PubMed Central  Google Scholar 

  • Feinstone SM, Kapikian AZ, Purcell RH (1973) Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182:1026–1028

    Article  CAS  PubMed  Google Scholar 

  • Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV (1975) Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 292:767–770

    Article  CAS  PubMed  Google Scholar 

  • Feld JJ (2012) Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology 142(6):1356–9. doi:10.1053/j.gastro.2011.12.064

    Article  PubMed  Google Scholar 

  • Flint M, Logvinoff C, Rice CM, McKeating JA (2004) Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J Virol 78(13):6875–6882

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS USA 102(8):2986–2991. Epub 2005 Feb 14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB (2010) Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28(38):6367–6373. doi:10.1016/j.vaccine.2010.06.084. Epub 2010 Jul 7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O’Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465(7294):96–100. doi:10.1038/nature08960. Epub 2010 Apr 21

    Article  CAS  PubMed  Google Scholar 

  • Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3(94):94ra71. doi:10.1126/scitranslmed.3002330

    Article  CAS  PubMed  Google Scholar 

  • Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645):659–662

    Article  CAS  PubMed  Google Scholar 

  • Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74(22):10407–10416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hollinger FB, Mosley JW, Szmuness W, Aach RD, Peters RL, Stevens C (1980) Transfusion-transmitted viruses study: experimental evidence for two non-A, non-B, hepatitis agents. J Infect Dis 142:400–407

    Article  CAS  PubMed  Google Scholar 

  • Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315(25):1575–1578

    Article  CAS  PubMed  Google Scholar 

  • Houghton M (2011) Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 239(1):99–108. doi:10.1111/j.1600-065X.2010.00977.x

    Article  CAS  PubMed  Google Scholar 

  • Houghton M, Abrignani S (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436(7053):961–966

    Article  CAS  PubMed  Google Scholar 

  • Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr et al (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. PNAS USA 104:5848–5853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M, Tsugane S, Japan Public Health Center-Based Prospective Study Group (2009) Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 18(6):1746–1753. doi:10.1158/1055-9965.EPI-08-0923

    Article  PubMed  Google Scholar 

  • Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, Abrignani S, Miyamura T (1998) High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28(4):1117–1120

    Article  CAS  PubMed  Google Scholar 

  • Khalaf N, White D, Kanwal F, Ramsey D, Mittal S, Tavakoli-Tabasi S, Kuzniarek J, El-Serag HB (2015) Coffee and caffeine are associated with decreased risk of advanced hepatic fibrosis among patients with hepatitis C. Clin Gastroenterol Hepatol 13(8):1521–1531.e3. doi:10.1016/j.cgh.2015.01.030. Epub 2015 Mar 14

    Article  CAS  PubMed  Google Scholar 

  • Kiyosawa K, Akahane Y, Nagata A, Furuta S (1984) Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 79(10):777–781

    CAS  PubMed  Google Scholar 

  • Kubo Y, Takeuchi K, Boonmar S, Katayama T, Choo QL, Kuo G, Weiner AJ, Bradley DW, Houghton M, Saito I et al (1989) A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res 17(24):10367–10372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH et al (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364

    Article  CAS  PubMed  Google Scholar 

  • Lai GY, Weinstein SJ, Albanes D, Taylor PR, McGlynn KA, Virtamo J, Sinha R, Freedman ND (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 109(5):1344–1351. doi:10.1038/bjc.2013.405. Epub 2013 Jul 23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL (2005) Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79(10):6023–6034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M (2013) A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 8(3):e59776. doi:10.1371/journal.pone.0059776. Epub 2013 Mar 19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the toll-like receptor 3 adaptor protein TRIF. PNAS USA 102(8):2992–2997. Epub 2005 Feb 14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lindenbach BD, Rice CM (2013) The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11(10):688–700. doi:10.1038/nrmicro3098. Epub 2013 Sep 10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424):110–113

    Article  CAS  PubMed  Google Scholar 

  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plusribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965

    Article  CAS  PubMed  Google Scholar 

  • McHutchison JG, Fried MW (2003) Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 7(1):149–161

    Article  PubMed  Google Scholar 

  • Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7(8):927–933

    Article  CAS  PubMed  Google Scholar 

  • Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G (2011) In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53(3):755–762. doi:10.1002/hep.24171. Epub 2011 Feb 11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH (2011) Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 204(8):1186–1190. doi:10.1093/infdis/jir511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9(9):1089–1097. Epub 2007 Aug 26. Erratum in: Nat Cell Biol. 2007 Oct;9(10):1216

    Article  CAS  PubMed  Google Scholar 

  • Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 51(1):201–209. doi:10.1002/hep.23279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moradpour D, Gosert R, Egger D, Penin F, Blum HE, Bienz K (2003) Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 60(2):103–109

    Article  CAS  PubMed  Google Scholar 

  • Neufeldt CJ, Joyce MA, Levin A, Steenbergen RH, Pang D, Shields J, Tyrrell DL, Wozniak RW (2013) Hepatitis C virus-induced cytoplasmic organelles use the nuclear transport machinery to establish an environment conducive to virus replication. PLoS Pathog 9(10):e1003744. doi:10.1371/journal.ppat.1003744. Epub 2013 Oct 31

    Article  PubMed  PubMed Central  Google Scholar 

  • Nyalakonda H, Utay NS (2015) A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis 28(5):471–478

    Article  CAS  PubMed  Google Scholar 

  • Ohfuji S, Fukushima W, Tanaka T, Habu D, Tamori A, Sakaguchi H, Takeda T, Kawada N, Seki S, Nishiguchi S, Shiomi S, Hirota Y (2006) Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study. Hepatol Res 36(3):201–208. Epub 2006 Aug 17

    Article  CAS  PubMed  Google Scholar 

  • Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC (2014) Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59(6):2140–2151. doi:10.1002/hep.27013. Epub 2014 Apr 29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Paul D, Madan V, Bartenschlager R (2014) Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 16(5):569–579. doi:10.1016/j.chom.2014.10.008. Epub 2014 Nov 12

    Article  CAS  PubMed  Google Scholar 

  • Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. PNAS USA 104(14):6025–6030. Epub 2007 Mar 28

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prince AM (1983) Non-A, non-B hepatitis viruses. Annu Rev Microbiol 37:217–232

    Article  CAS  PubMed  Google Scholar 

  • Prince AM, Brotman B, Grady GF, Kuhns WJ, Hazzi C, Levine RW, Millian SJ (1974) Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 2(7875):241–246

    Article  CAS  PubMed  Google Scholar 

  • Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Selby M, Kuo G, Houghton M, Choo QL (1993) Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 67(11):6753–6761

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, Houghton M, Frey SE, Belshe RB (2010) Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 202(6):862–866. doi:10.1086/655902

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Romero-Brey I, Berger C, Kallis S, Kolovou A, Paul D, Lohmann V, Bartenschlager R (2015) NS5A domain 1 and polyprotein cleavage kinetics are critical for induction of double-membrane vesicles associated with hepatitis C virus replication. Mol Biol 6(4). pii: e00759-15. doi:10.1128/mBio.00759-15

  • Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B (2005) Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol 86(Pt 12):3189–3199

    Article  CAS  PubMed  Google Scholar 

  • Shih JW, Mur JI, Alter HJ (1986) Non-A, non-B hepatitis: advances and unfulfilled expectations of the first decade. Prog Liver Dis 8:433–452

    CAS  PubMed  Google Scholar 

  • Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM (2003) Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197(12):1645–1655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59(1):318–327. doi:10.1002/hep.26744

    Article  PubMed  Google Scholar 

  • Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M (2007) Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25(45):7773–7784. Epub 2007 Sep 14

    Article  CAS  PubMed  Google Scholar 

  • Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6(261):261ra153. doi:10.1126/scitranslmed.3009185

    Article  PubMed  PubMed Central  Google Scholar 

  • Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11(7):791–796. Epub 2005 Jun 12. Erratum in: Nat Med. 2005 Aug;11(8):905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, Frey SE, Belshe RB, Tyrrell DL, Law JL, Houghton M (2014) Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol 88(24):14278–14288. doi:10.1128/JVI.01911-14. Epub 2014 Oct 1

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

I would like to thank Amy Weiner, Kang-Sheng Wang and the late Lacy Overby for their many valuable inputs and contributions and I dedicate this review to the memory of Lacy, a mentor, friend, colleague and a great enthusiast of medical science.

Author information

Authors and Affiliations

  1. Department of Medical Microbiology and Immunology, Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, Canada

    Michael Houghton Ph.D.

Authors
  1. Michael Houghton Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Houghton Ph.D. .

Editor information

Editors and Affiliations

  1. National Institute of Infectious Diseases, Tokyo, Tokyo, Japan

    Tatsuo Miyamura

  2. Departments of Medicine and Microbiology & Immunology , The University of North Carolina, Chapel Hill, North Carolina, USA

    Stanley M. Lemon

  3. Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA

    Christopher M. Walker

  4. National Institute of Infectious Diseases, Tokyo, Tokyo, Japan

    Takaji Wakita

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Houghton, M. (2016). Towards the Control of Hepatitis C. In: Miyamura, T., Lemon, S., Walker, C., Wakita, T. (eds) Hepatitis C Virus I. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56098-2_1

Download citation

Publish with us

Policies and ethics

Search

Navigation